日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology

贝叶斯中期分析在血液肿瘤学随机II期和III期临床试验中的附加价值

Smit, Anna J T; Van der Maas, Niek G; Van der Holt, Bronno; Van Norden, Yvette; Van Werkhoven, Erik; Vangsted, Annette Juul; Ypma, Paula F; Visser-Wisselaar, Heleen A; Troia, Rossella; Boccadoro, Mario; Löwenberg, Bob; Janssen, Jeroen J W M; Ossenkoppele, Gert J; Schjesvold, Fredrik; Sonneveld, Pieter; Zweegman, Sonja; Versluis, Jurjen; Cornelissen, Jan J

Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial

随机临床试验中的适应性设计:HOVON87/NMSG18 多发性骨髓瘤试验的重新分析

Seefat, Maarten R; van der Maas, Niek G; Nasserinejad, Kazem; van der Holt, Bronno; Waage, Anders; Mellqvist, Ulf-Henrik; Vangsted, Annette Juul; Smit, Anna J T; Smits, Febe; Ypma, Paula F; van de Donk, Niels W C J; Blommestein, Hedwig M; Cornelissen, Jan J; Cucchi, David G J; Zweegman, Sonja; Versluis, Jurjen

Obituary Acad. Prof. Dr. Vinko V. Dolenc 1940 - 2025

讣告学院。 Vinko V. Dolenc 教授、博士 1940 - 2025

Dirven, Thomas L A; Kappen, Pablo R; van der Beek, Frederike Ten Harmsen; van der Holt, Bronno; Jeekel, Hans; Dirven, Clemens M F; Vincent, Arnaud J P E; Klimek, Markus; Poley, Marten J; Bošnjak, Roman

Time-restricted versus standard-duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON-96 trial

异基因造血干细胞移植后限时免疫抑制与标准疗程免疫抑制的比较:前瞻性随机HOVON-96试验的结果

Broers, Annoek E C; Meijer, Ellen; van der Holt, Bronno; de Jong, Cornelis N; Nur, Erfan; van Sluis, Geerte L; Choi, Goda; van Gelder, Michel; Maertens, Johan A; Kuball, Jürgen; Deeren, Dries; Visser-Wisselaar, Heleen A; Meulendijks, Lamberdina A H M; Cornelissen, Jan J

Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial

在接受大剂量硼替佐米治疗且符合移植条件的初诊多发性骨髓瘤患者中,接受硼替佐米治疗前后的疗效:来自 III 期 HOVON-65/GMMG-HD4 试验的 10 年以上随访后的长期总生存期

Mai, Elias K; Nogai, Axel; Lokhorst, Henk M; van der Holt, Bronno; Zweegman, Sonja; Weisel, Katja C; Croockewit, Sandra; Jauch, Anna; Hillengass, Jens; Stevens-Kroef, Marian; Raab, Marc S; Broijl, Annemiek; Bos, Gerard M J; Brossart, Peter; Ypma, Paula; Hanoun, Christine; Bertsch, Uta; Hielscher, Thomas; Salwender, Hans J; Scheid, Christoph; Goldschmidt, Hartmut; Sonneveld, Pieter

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

新诊断多发性骨髓瘤早期发病率和死亡率的预测因素:来自 3700 例患者的 5 项随机、对照、III 期试验的数据

Mai, Elias K; Hielscher, Thomas; Bertsch, Uta; Salwender, Hans J; Zweegman, Sonja; Raab, Marc S; Munder, Markus; Pantani, Lucia; Mancuso, Katia; Brossart, Peter; Beksac, Meral; Blau, Igor W; Dürig, Jan; Besemer, Britta; Fenk, Roland; Reimer, Peter; van der Holt, Bronno; Hänel, Mathias; von Metzler, Ivana; Graeven, Ullrich; Müller-Tidow, Carsten; Boccadoro, Mario; Scheid, Christof; Dimopoulos, Meletios A; Hillengass, Jens; Weisel, Katja C; Cavo, Michele; Sonneveld, Pieter; Goldschmidt, Hartmut

Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study

利妥昔单抗-甲氨蝶呤、卡莫司汀、替尼泊苷和泼尼松龙治疗原发性中枢神经系统淋巴瘤后的生存率、神经认知功能和健康相关生活质量结局:HOVON 105/ALLG NHL 24 研究的最终结果

Bromberg, Jacoline E C; Issa, Samar; van der Holt, Bronno; van der Meulen, Matthijs; Dirven, Linda; Minnema, Monique C; Seute, Tatjana; Durian, Marc; Cull, Gavin; van der Poel, Marjolein W M; Stevens, Wendy B C; Zijlstra, Josee M; Brandsma, Dieta; Nijland, Marcel; Mason, Kylie D; Beeker, Aart; Abrahamse-Testroote, Martine C J; van den Bent, Martin J; de Jong, Daphne; Doorduijn, Jeanette K

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

Teclistamab 会损害既往接受过大量治疗的多发性骨髓瘤患者的体液免疫:补充免疫球蛋白的重要性

Frerichs, Kristine A; Verkleij, Christie P M; Mateos, Maria Victoria; Martin, Thomas G; Rodriguez, Cesar; Nooka, Ajay; Banerjee, Arnob; Chastain, Katherine; Perales-Puchalt, Alfredo; Stephenson, Tara; Uhlar, Clarissa; Kobos, Rachel; van der Holt, Bronno; Kruyswijk, Sandy; Kuipers, Maria T; Groen, Kaz; Vishwamitra, Deeksha; Skerget, Sheri; Cortes-Selva, Diana; Doyle, Margaret; Zaaijer, Hans L; Zweegman, Sonja; Verona, Raluca I; van de Donk, Niels W C J

Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling

通过多状态模型深入研究克拉屈滨治疗成人急性淋巴细胞白血病的获益和风险

Hermans, Sjoerd J F; van Norden, Yvette; Versluis, Jurjen; Rijneveld, Anita W; van der Holt, Bronno; de Weerdt, Okke; Biemond, Bart J; van de Loosdrecht, Arjan A; van der Wagen, Lotte E; Bellido, Mar; van Gelder, Michel; van der Velden, Walter J F M; Selleslag, Dominik; van Lammeren-Venema, Daniëlle; van der Velden, Vincent H J; de Wreede, Liesbeth C; Postmus, Douwe; Pignatti, Francesco; Cornelissen, Jan J

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

对于不适合移植的新诊断多发性骨髓瘤患者,采用伊沙佐米-沙利度胺-地塞米松诱导治疗,随后进行伊沙佐米或安慰剂维持治疗:HOVON-126/NMSG 21.13 研究的长期结果

Groen, Kazimierz; Schjesvold, Fredrik H; van der Holt, Bronno; Levin, Mark-David; Seefat, Maarten R; Hansson, Markus; Leys, Maria B L; Regelink, Josien C; Waage, Anders; Szatkowski, Damian; Axelsson, Per; Hieu Do, Trung; Svirskaite, Asta; van der Spek, Ellen; Haukas, Einar; Knut-Bojanowska, Dorota; Ypma, Paula F; Blimark, Cecilie H; Mellqvist, Ulf-Henrik; van de Donk, Niels W C J; Sonneveld, Pieter; Klostergaard, Anja; Vangsted, Annette J; Abildgaard, Niels; Zweegman, Sonja